SCHEMBL3405592

SCHEMBL3405592

Fc1ccc(-c2ncc(CN3CCN(C4CCC4)CC3)[nH]2)c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.47
DRD4 P21917 7/20 0.43
DRD2 P14416 4/20 0.43
DRD3 P35462 4/20 0.43
HTR1A P08908 1/20 0.42
HTR3A P46098 1/20 0.42
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
KMT2A Q03164 1/20 0.40
TRPV6 Q9H1D0 2/20 0.38
KDM4E B2RXH2 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GLA P06280 1/20 0.37
SIGMAR1 Q99720 4/20 0.36
TMEM97 Q5BJF2 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3399872 0.98 CYP2D6 (0.47) CYP2D6DRD4DRD2DRD3HTR1A
SCHEMBL3403856 0.87 DRD4 (0.43) CYP2D6DRD4DRD2DRD3HTR1A
SCHEMBL3403443 0.86 SIGMAR1 (0.47) CYP2D6DRD4DRD2DRD3HTR1A
SCHEMBL3400725 0.85 ALDH1A1 (0.43) CYP2D6DRD4DRD2DRD3HTR1A
SCHEMBL3405212 0.84 SIGMAR1 (0.49) CYP2D6DRD4DRD2DRD3HTR1A
SCHEMBL3405477 0.77 SIGMAR1 (0.42) CYP2D6DRD4DRD2DRD3HTR1A
SCHEMBL3400917 0.77 ALDH1A1 (0.46) CYP2D6DRD4DRD2DRD3HTR1A
SCHEMBL3404406 0.76 SIGMAR1 (0.43) CYP2D6DRD4DRD2DRD3HTR1A
SCHEMBL3402538 0.73 SIGMAR1 (0.39) CYP2D6DRD4DRD2DRD3HTR1A
SCHEMBL3402137 0.71 SIGMAR1 (0.41) CYP2D6DRD4DRD2DRD3HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 CYP2D6 2046/4885DRD4 2958/4885DRD2 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.